Immunotherapy with antibodies blocking the immune checkpoint molecules PD-1, PD-L1 and CTLA-4 has become standard of care for patients with metastatic NSCLC not harboring oncogenic mutations of EGFR, ALK, ROS1 or RET21,22,29–34. Here, CTLA4 is linked to non-small cell lung carcinoma.